Aberdeen Group plc Has $12.46 Million Stake in Catalyst Pharmaceuticals, Inc. $CPRX
Aberdeen Group plc reduced its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 8.2% in Q3, now holding 632,441 shares valued at $12.46 million. Despite some insider selling, institutional investors own 79.22% of the company, and analysts maintain a consensus "Buy" rating with an average target price of $33.20. The biopharmaceutical company, with a market cap of $3.00 billion, focuses on therapies for rare neuromuscular, neurological, and metabolic diseases.
Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for
Catalyst Pharmaceutical (CPRX) is projected to report a year-over-year decline in earnings and lower revenues for the quarter ending December 2025. The company's upcoming earnings report, expected on February 25, will determine the stock's short-term price movement based on how actual results compare to estimates. Despite a history of beating EPS estimates, Catalyst currently has a negative Earnings ESP, making a conclusive prediction for a beat difficult.
Catalyst Pharmaceuticals (CPRX) Expected to Announce Earnings on Wednesday
Catalyst Pharmaceuticals (CPRX) is scheduled to release its Q4 2025 earnings before market open on Wednesday, February 25th, with analysts forecasting earnings of $0.42 per share. The earnings call is set for February 26th at 8:30 AM ET. Shares recently opened at $24.64, and the company has a consensus "Buy" rating with an average price target of $33.20 from analysts.
Public Sector Pension Investment Board Grows Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX
The Public Sector Pension Investment Board increased its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 10.8% in Q3, now owning 516,745 shares valued at $10.18 million. Other institutional investors also adjusted their holdings, with hedge funds owning 79.22% of the company's stock. Analysts have largely maintained a "Buy" rating for Catalyst Pharmaceuticals, with an average target price of $33.20.
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced it will release its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after market close. The company will host a conference call and webcast on Thursday, February 26, 2026, at 8:30 AM ET to discuss these results and provide a business update. Details for accessing the webcast and dial-in numbers for the conference call are provided.
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Catalyst Pharmaceuticals, Inc. announced it will release its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after market close. The company will then host a conference call and webcast on Thursday, February 26, 2026, at 8:30 AM ET to discuss the results and provide a business update. This biopharmaceutical company focuses on developing and commercializing novel medicines for rare diseases.
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Catalyst Pharmaceuticals, Inc. announced it will release its fourth quarter and full-year 2025 financial results on February 25, 2026, after market close. The company will also host a conference call and webcast on February 26, 2026, at 8:30 AM ET to discuss these results and provide a business update. Catalyst Pharmaceuticals is a biopharmaceutical company focused on rare diseases, recognized by Forbes and Deloitte.
Catalyst Pharmaceuticals (CPRX) Investor Outlook: A Promising 41.4% Upside Potential
Catalyst Pharmaceuticals (CPRX) shows strong investor appeal with a 41.4% potential upside according to analysts. The biopharmaceutical company, focused on rare disease treatments, boasts robust financial performance including 15.30% revenue growth and a 27.52% return on equity. With unanimous buy ratings from analysts and a strategic focus on a niche market, CPRX is positioned for continued growth despite not offering dividends.
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Renewed Interest And Pocket Pivot Signal
Catalyst Pharmaceuticals (CPRX) has seen renewed interest due to strong financial performance, high profitability, and a debt-free balance sheet, with a recent "Pocket Pivot" signal. Despite a recent share price of $24.45 and an analyst target of US$34.57, the company is considered undervalued with a fair value estimated at $34.29, driven by demand for rare disease treatments and robust cash flow. However, reliance on FIRDAPSE and potential erosion of FYCOMPA exclusivity pose risks to this optimistic outlook.
Allianz Asset Management GmbH Cuts Stake in Catalyst Pharmaceuticals, Inc. $CPRX
Allianz Asset Management GmbH reduced its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 23.1% in Q3, selling 239,863 shares and now holding 797,948 shares worth $15.72 million. Catalyst Pharmaceuticals surpassed Q3 earnings expectations with $0.68 EPS and $148.4 million in revenue, maintaining a "Buy" consensus rating and a $33.20 target price from analysts. Insider transactions show notable sales by Carmen Jeffrey Del and Molly Harper, while institutional investors own 79.22% of the company's stock.
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Growth with Bullish Technical Setup
The article discusses Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) as a potential investment, highlighting its strong fundamental growth and bullish technical setup. CPRX exhibits robust revenue and EPS growth, high profitability, a clean balance sheet, and a moderate valuation. Technically, the stock shows a positive long-term trend, a consolidation phase, and positive volume signals, suggesting a potential for upward price movement.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of "Buy" from Brokerages
Catalyst Pharmaceuticals (NASDAQ:CPRX) has received a consensus "Buy" rating from eight brokerages, with an average 12-month price target of $33.20. The company recently reported strong quarterly earnings, surpassing EPS and revenue expectations, and showcasing healthy net margins and return on equity. Despite some recent insider selling, institutional investors and hedge funds significantly increased their positions, now holding approximately 79% of the company's stock.
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Growth Strength And Positive Analyst Sentiment
Catalyst Pharmaceuticals (CPRX) is gaining investor interest due to strong growth, profitability, and a debt-free balance sheet, leading to a "29.1% Undervalued" narrative with a fair value of $34.29. Despite positive analyst sentiment, the valuation hinges on Firdapse's concentration and patent litigation, alongside challenges from Fycompa's loss of exclusivity. The article suggests further research into the company's specifics and encourages exploring other investment opportunities.
Does Strong Financials And Rare-Disease Partnerships Change The Bull Case For Catalyst Pharmaceuticals (CPRX)?
Catalyst Pharmaceuticals, Inc. (CPRX) has been highlighted for its strong financials, including robust earnings, high returns on equity, and a debt-free balance sheet, further supported by a buyback program and raised revenue guidance. The company's focus on rare-disease therapies and partnerships with BioMarin and Endo Ventures are key differentiators, amplifying existing catalysts for growth. While the investment narrative is positive, risks include product concentration, regulatory pressures, and recent insider selling, alongside diverse fair value estimates from investors.
Ruffer LLP Makes New Investment in Catalyst Pharmaceuticals, Inc. $CPRX
Ruffer LLP has acquired a new stake of 108,616 shares (valued at approximately $2.14 million) in Catalyst Pharmaceuticals (NASDAQ:CPRX), indicating significant institutional interest, with institutional investors now owning about 79.22% of the stock. The company recently surpassed Q3 earnings expectations with an EPS of $0.68 and revenue of $148.4 million, maintaining strong profitability. Despite some insider selling, the board authorized a $200 million stock buyback program, suggesting management views the stock as undervalued.
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Screens as an Affordable Growth Stock
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) has been identified as an "affordable growth" stock, fitting the Growth at a Reasonable Price (GARP) strategy. The company demonstrates strong growth in earnings and revenue with a high ChartMill Growth Rating of 9 out of 10, while maintaining a sensible valuation with a P/E ratio significantly lower than its industry peers and the S&P 500. Additionally, CPRX exhibits robust profitability and financial health, characterized by strong margins and a debt-free balance sheet, providing a stable foundation for continued growth.
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
This article from Zacks Equity Research identifies Catalyst Pharmaceutical (CPRX) as a top momentum stock for long-term investment. It suggests that investors looking for strong growth potential should consider CPRX. The article also encourages readers to download a free report on 7 Best Stocks for the Next 30 Days.
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd significantly increased its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 1,216.5% in Q3, now owning 165,496 shares valued at $3.26 million. Despite insider selling by two executives, analysts maintain a "Buy" consensus with an average price target of $33.20. The company also reported an earnings beat and authorized a $200 million share buyback program.
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?
Catalyst Pharmaceuticals (NASDAQ:CPRX) recently traded above its 200-day moving average, reaching $24.83, with analysts maintaining a "Buy" consensus and a $33.20 price target. The company reported strong quarterly earnings and authorized a $200 million stock buyback program, despite recent insider share sales. Institutional investors are increasing their holdings, while insider ownership remains at 10.40%.
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Fresh Rare Disease Momentum And Earnings Outperformance
The article analyzes Catalyst Pharmaceuticals (CPRX) after recent developments in its rare disease portfolio and strong earnings. It highlights CPRX's undervaluation based on a P/E ratio of 13.2x compared to the industry average of 19.8x and a peer group average of 60.1x. Additionally, a discounted cash flow (DCF) model suggests the stock is deeply undervalued with an estimated future cash flow value significantly higher than its current share price.
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Value Investment Case
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) is highlighted as a compelling value investment due to its strong fundamental analysis,
Catalyst Pharmaceuticals, Inc. (CPRX): A Bull Case Theory
This article summarizes a bullish thesis on Catalyst Pharmaceuticals, Inc. (CPRX), focusing on its leading rare-disease biopharma position with key drugs FIRDAPSE and AGAMREE. The company demonstrates strong financial health with significant cash, no debt, and a share repurchase program, alongside promising growth catalysts. Its robust portfolio and strategic financial position suggest significant upside potential in the rare-disease sector.
Catalyst Pharmaceuticals, Inc. (CPRX): A Bull Case Theory
This article summarizes a bullish thesis on Catalyst Pharmaceuticals (CPRX), a rare-disease biopharma company. The company's strategy is centered on FIRDAPSE for LEMS and AGAMREE for DMD, both of which have strong market positions and growth drivers. Financially, Catalyst reported strong Q2 2025 revenues, a healthy net income, and a solid cash position with no debt, positioning it for significant upside potential.
How Investors May Respond To Catalyst Pharmaceuticals (CPRX) Rare-Disease Strength And Potential Technical Breakout
Catalyst Pharmaceuticals is showing strong fundamental growth and profitability in its rare disease franchise, primarily driven by FIRDAPSE and AGAMREE, with updated 2025 revenue guidance of US$565 million to US$585 million. Technical chart patterns also suggest a potential breakout, drawing investor attention despite the company still trading at a relatively low earnings multiple compared to peers. However, investors should remain aware of concentration risk tied to FIRDAPSE and ongoing patent litigation.
Jim Cramer on Catalyst Pharmaceuticals: “It’s a Very Inexpensive Stock”
Jim Cramer has recently commented on Catalyst Pharmaceuticals (NASDAQ: CPRX), calling it a "very inexpensive stock" with "real earnings," and a "winner." He acknowledged that while the stock has had a strong year, it is still a small-cap with some insider selling, and has declined by about 13% since his previous positive remarks in March 2025. Despite the risk, the article suggests that other AI stocks might offer higher returns.
SG Americas Securities LLC Raises Holdings in Catalyst Pharmaceuticals, Inc. $CPRX
SG Americas Securities LLC significantly increased its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 957.5% in Q3 2025, now owning 83,690 shares valued at $1.65 million. This comes as Catalyst Pharmaceuticals has a consensus "Buy" rating from analysts with a target price of $33.20, recently exceeded Q3 EPS and revenue estimates, and authorized a $200 million share repurchase program. However, some insider selling by Director Molly Harper and insider Carmen Jeffrey Del has also been noted.
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Fundamentals with a Technical Breakout Setup
The article highlights Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) as a strong growth stock combining robust fundamentals with a technical breakout setup. It details CPRX's high scores in growth, profitability, and financial health, alongside a favorable chart formation suggesting a potential price increase. The company's fair valuation, despite strong performance, is also emphasized as a key advantage for investors.
Catalyst Pharmaceuticals, Inc. Presents at JP Morgan Healthcare Conference
Catalyst Pharmaceuticals, Inc. announced its participation in the 44th Annual JP Morgan Healthcare Conference on January 12, 2026. The company highlighted strong financial performance, including 227% annual revenue growth for AGAMREE in 2025 and maintaining over $700M in cash with no funded debt. Catalyst also updated its 2025 revenue guidance to $565M-$585M and secured FIRDAPSE market exclusivity until 2035 through patent litigation settlement.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of "Buy" from Analysts
Catalyst Pharmaceuticals (NASDAQ:CPRX) has received a consensus "Buy" rating from nine analysts, with an average one-year price target of $33.20. The company's board has authorized a $200 million share repurchase program, indicating management's belief that the stock may be undervalued. Despite significant insider selling, institutional investors hold a substantial portion of the company's stock.
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Forbes 2026 Small Cap Recognition
Catalyst Pharmaceuticals (CPRX) has gained recognition from Forbes as one of America's Most Successful Small-Cap Companies for 2026, driven by strong sales growth and financial performance. Despite recent cooling in its share price momentum, the company is considered undervalued with a fair value of $34.29 compared to its closing price of US$22.72. The valuation is supported by an increasing eligible patient pool for its rare disease treatments, though it faces risks from patent litigation and generic pressure.
How Forbes’ Small-Cap Accolade Will Impact Catalyst Pharmaceuticals (CPRX) Investors
Forbes recently ranked Catalyst Pharmaceuticals 11th on its 2026 list of America's Most Successful Small-Cap Companies, providing external validation for the rare disease drugmaker. While this accolade is positive, the article emphasizes that investors should continue to focus on the upcoming FIRDAPSE patent trial and the potential impact of generics, as the company remains highly exposed to its core product. Despite a projected revenue increase and a fair value estimate significantly above its current price, a wide range of analyst opinions highlights the importance of considering multiple perspectives due to concentration risk and ongoing litigation.
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
Catalyst Pharmaceuticals, Inc. has been recognized on Forbes' 2026 list of America's Most Successful Small-Cap Companies, ranking an impressive 11th out of 100. This marks the fourth consecutive year the company has received this honor, reflecting its strong financial performance and dedication to rare disease patient communities. The ranking criteria included positive sales growth, share price, and growth in earnings, sales, return on equity, and total stock return over five years.
Santhera Seals APAC Pact For Agamree
Santhera has announced a partnership agreement for Agamree in the APAC region. The alliance aims to expand the reach of the drug, particularly in key markets like Japan, Australia, South Korea, and New Zealand. This strategic move is expected to enhance access to Agamree for patients with rare diseases in these territories.
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) was ranked 11th on Forbes' 2026 list of America's Most Successful Small-Cap Companies. This recognition reflects the company's strong performance, commitment to rare disease patient communities, and growth in earnings, sales, and stock return over the past five years. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing novel medicines for rare diseases.
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Prospects Need A Boost To Lift Shares
Catalyst Pharmaceuticals (NASDAQ:CPRX) has a low price-to-earnings (P/E) ratio of 13.2x, which suggests it might be undervalued given that many US companies have higher P/E ratios. However, this low P/E is likely due to analyst forecasts predicting a lower future earnings growth rate of 3.4% annually, compared to the broader market's 11% forecast. Investors seem cautious about the company's future prospects, hindering a potential increase in its share price.
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
The University of Notre Dame and Catalyst Pharmaceuticals have launched their inaugural Catalyst Advocacy Scholars Summit (CASS), a program designed to give students an immersive learning experience in biopharmaceutical patient advocacy. Twelve students from Notre Dame's Patient Advocacy Minor Department will participate in the week-long summit in Coral Gables, Florida, aiming to attract top talent to the biopharmaceutical industry and deepen patient focus in scientific programs. Catalyst Pharmaceuticals, a biopharmaceutical company focused on rare diseases, hopes to benefit from the students' fresh perspectives on their ongoing programs.
How 12 Notre Dame students will spend a week inside rare disease care
Catalyst Pharmaceuticals and the University of Notre Dame have launched the inaugural Catalyst Advocacy Scholars Summit (CASS), a week-long immersive program from January 5–9, 2026, for 12 Notre Dame students specializing in Patient Advocacy. The summit aims to educate students on patient advocacy and biopharmaceutical operations, while also providing Catalyst Pharmaceuticals with fresh student perspectives on their programs. This collaboration seeks to attract talent to the biopharmaceutical industry and enhance the patient-centric focus in scientific degree programs.
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
The University of Notre Dame and Catalyst Pharmaceuticals have launched their inaugural Catalyst Advocacy Scholars Summit (CASS), a program designed to immerse students in the biopharmaceutical industry's opportunities and challenges, particularly concerning rare diseases. Students selected from the university's Patient Advocacy Minor Department will gain insights into patient advocacy and biopharmaceutical operations. This initiative aims to attract top talent and integrate patient focus into scientific education while offering Catalyst fresh perspectives on its programs.
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
The University of Notre Dame and Catalyst Pharmaceuticals have partnered to launch the inaugural Catalyst Advocacy Scholars Summit (CASS). This program, designed for students from Notre Dame's Patient Advocacy Minor Department, offers an immersive learning experience focused on the biopharmaceutical industry and the challenges of delivering medicine for rare diseases. The summit, held from January 5-9, 2026, aims to attract top talent and foster a patient-centric mindset in future industry professionals.
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade
Catalyst Pharmaceuticals shares dropped 3% in afternoon trading, continuing a two-day slide, while biotech ETFs also underperformed the broader market in thin year-end trading. Investors are looking ahead to the Federal Reserve's meeting minutes and Catalyst's next public appearance in January. Analyst sentiment remains largely positive, with an average 12-month price target implying significant upside.
Voya Investment Management LLC Has $8.79 Million Position in Catalyst Pharmaceuticals, Inc. $CPRX
Voya Investment Management LLC increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 25.1% in the third quarter, now owning 446,399 shares valued at approximately $8.79 million. The biopharmaceutical company's board has also approved a $200 million share repurchase program, signaling management's belief that the stock is undervalued. Catalyst Pharmaceuticals has a consensus analyst "Buy" rating and a target price of around $32.67.
Texas Permanent School Fund Corp Boosts Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX
Texas Permanent School Fund Corp significantly increased its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 178.8% in Q2, bringing its total to 67,934 shares valued at $1.47 million. This move is part of a broader trend of institutional investors, including Goldman Sachs and Bank of America, increasing their positions in the biopharmaceutical company, which has seen its institutional ownership reach 79.22%. Catalyst Pharmaceuticals has also authorized a $200 million share buyback program, and Wall Street analysts currently rate the stock as a "Buy" with an average price target of $32.67.
Wedge Capital Management L L P NC Makes New $2.86 Million Investment in Catalyst Pharmaceuticals, Inc. $CPRX
Wedge Capital Management L L P NC has initiated a new position in Catalyst Pharmaceuticals (NASDAQ:CPRX) during the third quarter, acquiring 145,168 shares valued at approximately $2.86 million. This investment comes amid positive analyst sentiment, with an average "Buy" rating and a target price of $32.67 for the biopharmaceutical company. Catalyst Pharmaceuticals has also authorized a $200 million share repurchase program, indicating the board believes its shares are undervalued.
Catalyst Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains
Catalyst Pharmaceuticals Inc. stock underperformed its competitors on Wednesday, despite daily gains. The article briefly mentions Unity Software's fourth-quarter financial results, including a revenue increase of 35% year-over-year to $609 million and a quarterly loss of 66 cents per share. However, the full article content is restricted due to copyright issues.
Toth Financial Advisory Corp Has $42,000 Stake in Catalyst Pharmaceuticals, Inc. $CPRX
Toth Financial Advisory Corp significantly reduced its stake in Catalyst Pharmaceuticals (NASDAQ: CPRX) by 96.5% in Q3, now holding 2,150 shares valued at $42,000. Despite this, institutional ownership remains high at 79.22%, and analysts maintain an average "Buy" rating with an average target price of $32.67. Additionally, the company has approved a $200 million share repurchase program, indicating board confidence in the stock's value.
First Week of February 2026 Options Trading For Catalyst Pharmaceuticals (CPRX)
Catalyst Pharmaceuticals (CPRX) has seen new options trading for the February 2026 expiration. A specific call contract at the $30.00 strike price offers a potential total return of 25.99% if the stock is called away, given a current share price of $23.93. The implied odds of this out-of-the-money contract expiring worthless are 84%, providing a 0.63% premium boost to investors.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of "Buy" by Analysts
Catalyst Pharmaceuticals (NASDAQ:CPRX) has received an average "Buy" rating from ten research firms, with a mean 1-year price target of $32.67. The company's board has authorized a $200 million stock buyback, indicating a belief that shares may be undervalued, despite recent insider selling by two directors. Various institutional investors have also made changes to their holdings in the company.
Molly Harper Takes Money Off The Table, Sells $621K In Catalyst Pharmaceuticals Stock
Molly Harper, a Director at Catalyst Pharmaceuticals (NASDAQ: CPRX), recently sold 26,746 shares of the company's stock for a total of $621,920. This insider transaction comes as Catalyst Pharmaceuticals, a biopharmaceutical company focusing on rare diseases, shows positive revenue growth but below-average EPS when compared to industry norms. The company's financials indicate strong gross margins and low debt, alongside a potentially undervalued stock based on its P/E and EV/EBITDA ratios.
Catalyst Pharmaceuticals (NASDAQ:CPRX) Director Molly Harper Sells 26,746 Shares
Catalyst Pharmaceuticals (NASDAQ:CPRX) Director Molly Harper sold 26,746 shares, significantly reducing her stake in the company. Despite the insider sale, Catalyst Pharmaceuticals recently reported solid quarterly results and authorized a $200 million share buyback, suggesting confidence from the board in the company's valuation. Analyst consensus rates the stock as a "Buy" with a target price of $32.67.
Catalyst Pharmaceuticals CPRX Stock News, Forecasts and Analyst Outlook for December 15, 2025
Catalyst Pharmaceuticals (CPRX) is gaining attention due to its upcoming appearance at the J.P. Morgan Healthcare Conference, a strong 2025 performance, and a robust financial position. The company is balancing growth from FIRDAPSE and AGAMREE with managing generic competition for FYCOMPA, while analysts anticipate significant upside. Investors are watching for further updates on business development, AGAMREE's trajectory, and buyback execution.
